(Q47266542)

12 January 2018

title

Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination (English)

1 reference

12 January 2018

0 references

1 reference

1 reference

6

Abraham Weizman

1 reference

12 January 2018

author name string

Michael Poyurovsky

1

1 reference

12 January 2018

Camil Fuchs

2

1 reference

12 January 2018

Artashez Pashinian

3

1 reference

12 January 2018

Adva Levi

4

1 reference

12 January 2018

Ronit Weizman

5

1 reference

12 January 2018

publication date

13 December 2012

1 reference

12 January 2018

published in

Psychopharmacology

1 reference

12 January 2018

volume

226

1 reference

12 January 2018

issue

3

1 reference

12 January 2018

page(s)

615-622

1 reference

12 January 2018

Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Pharmacological management of atypical antipsychotic-induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Differential role of histamine in mediating stress-induced changes in central dopaminergic neuronal activity in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Binding affinity profile of betahistine and its metabolites for central histamine receptors of rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Histamine excites noradrenergic neurons in locus coeruleus in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A-induced wakefulness in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Metabolic drug interactions with new psychotropic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2935-2

Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus

21 January 2018

1 reference

12 December 2020

Betahistine inhibits food intake in rats.

1 reference

12 December 2020

Novel antipsychotics: comparison of weight gain liabilities.

1 reference

12 December 2020

Effect of the H1-histamine receptor agonist betahistine on drinking and eating behavior in pygmy goats

1 reference

12 December 2020

Clinical efficacy of reboxetine in major depression

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

10.1007/S00213-012-2935-2

Identifiers

DOI

1 reference

12 January 2018

1 reference

12 January 2018